Lupin Pharmaceuticals Gets US FDA Nod for Its Renvela Generic Medicine


The pharmaceutical company ‘Lupin’ said that, it has successfully received the approval from the Food and Drug Administration (FDA) of the United States for the company’s ANDA (abbreviated new drug application) Sevelamer Carbonate for the oral suspension. This drug or medicine has been a generic equivalent of the Renvela for the oral suspension produced by the Genzyme Corporation.

Sevelamer has been used for controlling the high levels of blood of the phosphorus in the people suffering with the chronic kidney disease who are on their dialysis, and the company also said that, this product is going to be manufactured at the facility of Lupin located in Goa, India.

The Sevelamer Carbonate for the oral suspension had been estimated the annual sales of 51.7 million dollars in the United States, and the company ‘Lupin’ has been a transnational pharmaceutical company, and the company has also been developing and commercializing a wide a range of the generic and branded formulations, along with the APIs and the biotechnology products in more than 100 markets in the countries including South Africa, India, the United States, Asia Pacific, Middle East and also the region of Europe.

READ  UK: Scientists Urge Government to Expand Covid-19 Symptoms List